Aktis Oncology Inc Revenue Growth Rates (AKTS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Aktis Oncology Inc   (NASDAQ: AKTS)
    Sector • Technology    Industry • Consumer Electronics
   Industry • Consumer Electronics
   Sector • Technology
 

AKTS's Revenue Growth by Quarter and Year

Aktis Oncology Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/AKTS/growth
https://api.csimarket.com/api/v1/companies/AKTS/fundamentals
https://api.csimarket.com/api/v1/companies/AKTS/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
AKTS Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 3.91
2nd Quarter June 3.38
1st Quarter March 3.23
FY 10.52

AKTSs Annual Revenue
Aktis Oncology Inc 's Revenue in the fiscal year 2024 $ 27.38 millions
Aktis Oncology Inc 's Revenue in the fiscal year 2023 $ 27.12 millions
Aktis Oncology Inc 's Revenue in the fiscal year 2022 $ 15.35 millions
Aktis Oncology Inc 's Revenue in the fiscal year 2021 $ 6.62 millions
Aktis Oncology Inc 's Revenue in the fiscal year 2020 $ 1.79 millions




AKTS Revenue third quarter 2026 Y/Y Growth Comment
Aktis Oncology Inc achieved in the third quarter 2026, above Company average Revenue surge of 144.06% year on year, to $ 3.91 millions.

Looking into third quarter 2026 results within Consumer Electronics industry 3 other companies have achieved higher Revenue growth. While Aktis Oncology Inc ' s Revenue doubling of 144.06% ranks overall at the positon no. 194 in the third quarter 2026.


AKTS Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 144.06 %
2nd Quarter June 133.1 %
1st Quarter March -64.23 %
FY   -

Financial Statements
Aktis Oncology Inc 's third quarter 2026 Revenue $ 3.91 millions AKTS's Income Statement
Aktis Oncology Inc 's third quarter 2025 Revenue $ 1.60 millions Quarterly AKTS's Income Statement


AKTS Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 15.53 %
2nd Quarter June 4.64 %
1st Quarter March 104.43 %
FY (Year on Year)   -


Back to AKTS Growth rate Comparisons >> Back to AKTS Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Consumer Electronics Industry #4
Technology Sector #40
Overall #194

Revenue Y/Y Growth Statistics
High Average Low
863.84 % 103.31 % -100 %
(Sep 30 2021)   (Jun 30 2026)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Consumer Electronics Industry #4
Technology Sector #40
Overall #194
Revenue Y/Y Growth Statistics
High Average Low
863.84 % 103.31 % -100 %
(Sep 30 2021)   (Jun 30 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Aktis Oncology Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1529.87 % 55.07 % -100 %
(Sep 30 2017)  


AKTS's III. Quarter Q/Q Revenue Comment
Aktis Oncology Inc achieved in the III. Quarter 2026 below company average Revenue jump of 15.53% quarter on quarter, to $ 3.91 millions.

Although the III. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the 10.34% growth in the III. Quarter a year ago

Within Consumer Electronics industry 7 other companies have achieved higher Revenue quarter on quarter growth. While Aktis Oncology Inc 's Revenue growth quarter on quarter, overall rank is 1185.


Revenue Q/Q Growth Company Ranking
Within: No.
Consumer Electronics Industry #8
Technology Sector #186
Overall #1185
Revenue Q/Q Growth Company Ranking
Within: No.
Consumer Electronics Industry #8
Technology Sector #186
Overall #1185
Revenue Q/Q Growth Statistics
High Average Low
1529.87 % 55.07 % -100 %
(Sep 30 2017)  


AKTS's III. Quarter Q/Q Revenue Comment
Aktis Oncology Inc achieved in the III. Quarter 2026 below company average Revenue jump of 15.53% quarter on quarter, to $ 3.91 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 10.34% in the III. Quarter a year ago.

Within Consumer Electronics industry 7 other companies have achieved higher Revenue quarter on quarter growth. While Aktis Oncology Inc 's Revenue growth quarter on quarter, overall rank is 1185.


Aktis Oncology Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 12.10
Y / Y Revenue Growth (TTM) -32.54 %
Year on Year Revenue Growth Overall Ranking # 2310
Seqeuential Revenue Change (TTM) 23.53 %
Seq. Revenue Growth (TTM) Overall Ranking # 1786


Cumulative Revenue growth Comment
Aktis Oncology Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2026. If the fiscal year would end in Sep 30 2026, Aktis Oncology Inc 's annual Revenue increase would be -32.54% year on year to $12 millions.

In the Technology sector 376 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 151 to 2310.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Consumer Electronics Industry # 17
Technology Sector # 377
Overall # 2310

Revenue TTM Y/Y Growth Statistics
High Average Low
316.89 %
 69.68 %
-67.16 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 17
Sector # 316
S&P 500 # 1786
Cumulative Revenue growth Comment
Aktis Oncology Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2026. If the fiscal year would end in Sep 30 2026, Aktis Oncology Inc 's annual Revenue drop would be -32.54% year on year to $12 millions.

In the Technology sector 376 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 151 to 2310.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Consumer Electronics Industry # 17
Technology Sector # 377
Overall # 2310

Revenue TTM Y/Y Growth Statistics
High Average Low
316.89 %
69.68 %
-67.16 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 17
Sector # 316
S&P 500 # 1786




Other Revenue Growth
Consumer Electronics Industry Revenue Growth Trends and Statistics
Technology Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AKTS's Revenue Growth Ratio versus Consumer Electronics Industry, Technology Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2026 within Technology SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Quicklogic Corp236.26%$ 236.257 millions
Aurora Innovation Inc 200.00%$ 200.000 millions
Kulr Technology Group Inc 197.27%$ 197.272 millions
Cxapp Inc 169.75%$ 169.749 millions
Axt Inc169.65%$ 169.652 millions
Coreweave Inc 168.27%$ 168.269 millions
Senseonics Holdings Inc 161.93%$ 161.931 millions
SPACE EXPLORATION TECHNOLOGIES CORP161.39%$ 161.388 millions
Healthcare Triangle Inc 161.28%$ 161.278 millions
Astera Labs Inc 154.51%$ 154.512 millions
Snail Inc 154.04%$ 154.037 millions
Netlist Inc151.22%$ 151.217 millions
Aktis Oncology Inc 147.31%$ 147.308 millions
Lumentum Holdings Inc 145.88%$ 145.881 millions
Applied Optoelectronics Inc 128.20%$ 128.199 millions
Blacksky Technology Inc118.39%$ 118.391 millions
Ambiq Micro Inc 115.75%$ 115.749 millions
Compass Inc 111.11%$ 111.105 millions
Palantir Technologies Inc 95.92%$ 95.921 millions
Coursera Inc 94.18%$ 94.175 millions
Onto Innovation Inc 88.28%$ 88.283 millions
Celestica Inc 82.57%$ 82.572 millions
Qxo Inc 79.45%$ 79.449 millions
Vicor Corporation78.51%$ 78.508 millions
Paltalk Inc75.54%$ 75.539 millions
Maxlinear Inc 73.20%$ 73.197 millions


About Aktis Oncology Inc Revenue Growth Rates (AKTS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Akoustis Technologies Inc (CIK 1584754).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001213900-24-097800
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Akoustis Technologies Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.